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Introduction
Lower extremity injuries are a serious concern in the 
military, athletic, and other physically active populations1-3. 
Anterior cruciate ligament (ACL) injuries are of particular 
interest because of the significant loss of training time and 
potential for long-term complications such as post-traumatic 
osteoarthritis4. When controlling for competitive level, female 
athletes appear to be at a greater risk for ACL injuries than 
male athletes5. Ireland et al. reported that female basketball 
players tear their ACL at almost three times the rate of men6. 
The discrepancy may be even larger in military training with 
one study reporting a relative risk of 9.74 per 1000 athlete-
exposures for ACL injury for females compared to males7. 
These discrepancies necessitate further investigation into 
potential mechanisms for the greater incidence of ACL 
injuries in females with the goal of developing sex-specific 
prevention protocols.
While many mechanisms have been suggested, prior 
studies indicate that the increased risk is a function of 
musculoskeletal and hormonal risk factors8-11. Muscle force 
production is a key factor in reducing the risk of ACL injuries 
due to the stabilizing role of the quadriceps and hamstrings 
at the knee. Females have been reported to have weaker 
hamstrings than males12 and a lower hamstring-to-quadriceps 
strength ratio8 may increase their risk of non-contact knee 
injuries13. Additionally, greater knee joint laxity in females 
has been suggested as a potential reason for the disparity 
in injury rates between males and females12,14. Greater knee 
joint laxity would theoretically result in excessive motion 
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about the joint, thereby increasing the risk that forces on the 
ligament may exceed its yield point. However, several studies 
with small sample sizes and inconsistent methodology 
have investigated changes in knee joint laxity throughout 
the menstrual cycle with different studies indicating an 
association between knee joint laxity and menstrual cycle 
phases and some studies showing no association15-18.
Fluctuations in female sex hormones, combined with the 
proposed relationship of these hormones to joint laxity6,9, 
suggest that injury rates may fluctuate based on hormonal 
changes that occur throughout the menstrual cycle. Prior 
studies have reported that estrogen receptors are present 
in human ACL and skeletal muscle tissue and that fibroblast 
metabolism, myoblast growth, and collagen synthesis are all 
altered in the presence of estrogen19-21. The specific effects 
of estrogen on skeletal muscle have been studied extensively 
in post-menopausal women with one large meta-analysis 
reporting a beneficial effect of estrogen-based hormone 
replacement therapy on muscle strength22. While the 
underlying mechanism is not well understood, these studies 
suggest that as estrogen fluctuates throughout the menstrual 
cycle so might muscle force production and joint laxity. If this 
is the case, hormonal contraception could be associated with 
injuries by limiting the hormonal fluctuations and subsequent 
fluctuations in joint laxity and muscle function that occur 
during the cycle23. This is supported by previous studies 
investigating the association between ACL injury risk and 
contraceptive use that have indicated a protective effect of 
oral contraceptives on injury risk24,25. 
Relaxin is a hormone that is responsible for connective 
tissue changes late in pregnancy to accommodate childbirth. 
Due to its effect of reducing stiffness of tendons and 
ligaments, it is hypothesized that an increase in relaxin 
concentration could result in a decrease of force production 
as well as increased joint laxity. With the presence of relaxin 
specific binding sites on connective tissue in females, the 
mechanism exists for relaxin to act on these tissues26,27. 
This theoretical framework is supported by the results of 
a longitudinal investigation that found that an increase in 
serum relaxin concentration over 6 pg/mL was associated 
with a fourfold increase in ACL tears28.
Previous studies have suggested that a potential 
relationship may exist between menstrual cycle phase 
and ACL injury risk; however, the results of these studies 
are inconclusive with injury risk being reported as highest 
during each of the three phases in at least one study9,29-31. 
While extensive progress has been made in the area of sex 
differences in the risk of ACL injuries, much of the data 
have been inconclusive. The purpose of this study was to 
investigate changes in muscular strength and stamina, and 
joint laxity throughout the menstrual cycle and to determine 
how oral contraceptive (OC) use alters these findings. We 
hypothesized that changes in isokinetic peak torque, grip 
strength, and joint laxity over the menstrual cycle phases 
would be greater in the non-OC group than the OC group due 
to greater variablitily in hormone concentrations.
Methods
Participant information
Physically active females aged 18 to 25 years old (n=50) 
were recruited from South Dakota State University through 
on-campus advertising and through meetings with classes 
in the Health and Nutritional Sciences Department. Twenty-
five females who were taking OCs (monophasic) and twenty-
five women that were not taking OC were recruited. Three 
participants in the non-OC group who did not ovulate, and 
one participant in the OC group who was missing hormone 
measurements, were excluded from all analyses. The South 
Dakota State University Institutional Review Board approved 
this protocol and informed consent was obtained from all 
participants prior to the study. On the day of the initial visit, 
participants completed a physical activity readiness screening 
(PAR-Q) and filled out a health history questionnaire that 
included the number of days that they perform at least 30 
minutes of structured physical activity per week.
Inclusion and exclusion criteria
An initial questionnaire was administered to determine 
whether the menstrual cycle of potential participants was 
regular (every 21-35 days) and only those individuals with 
a regular menstrual cycle were invited to participate. In 
addition to cycles occurring every 21-35 days, menstrual 
regularity also included that participants had experienced 
menstrual bleeding in each of the past 3 months. For the OC 
group, only women who had been taking a monophasic OC 
for a minimum of 3 months prior to the study were invited 
to participate. Participants were excluded if they were using 
alternative contraception methods including vaginal rings, 
intrauterine devices, or injections. Participants were excluded 
if they had suffered any injury to their lower extremity in the 
past 6 months or had a previous ACL injury. 
Visit schedule and bias reduction
Participants completed three visits that were designed to 
coincide with the early-follicular, ovulatory, and mid-luteal 
phases of the menstrual cycle (Table 1). All participants were 
asked to contact the study coordinator on the first day of 
their menstrual cycle to schedule an appointment for their 
first testing session. This visit took place within 72 hours 
of the onset of menses. Participants who were taking OCs 
had their subsequent visit on cycle day 14 to 16 and their 
final visit 1 week after their second visit. Participants who 
were not taking OCs were asked to take a home ovulation 
test every day beginning at day 7 which indicated when the 
luteinizing hormone (LH) surge occurred prior to ovulation. 
When a positive test occurred, the participants were asked 
to contact the study coordinator and set up a visit within 48 
hours of the positive test. The final visit took place 7 days 
after the ovulation visit. 
In order to decrease the effect of diurnal variability of 
hormone concentrations on our results, all study visits 
were scheduled in the morning and all follow-up visits were 
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scheduled within 2 hours of the time that the early-follicular 
phase visit was performed. Additionally, participants were 
asked to refrain from moderate or vigorous physical activity 
for 24 hours prior to the visit. Participants completed a 24-
hour diet record using the ASA 24 (NIH, National Cancer 
Institute, Bethesda, MD) prior to each visit to ensure that 
dietary factors that may influence grip strength or isokinetic 
torque production were not different among visits. Finally, 
participants were asked to complete a menstrual symptom 
questionnaire at each visit to capture symptoms they may 
experience that could be attributed to their menstrual 
cycle. The instrument asked about musculoskeletal as well 
as psychological symptoms that may occur throughout the 
menstrual cycle. 
Anthropometrics
Anthropometric measurements were taken in duplicate. 
Height without shoes was measured to the nearest 0.5 cm 
using a portable stadiometer (Seca Model 225). Weight was 
measured to the nearest 0.1 kg using a digital scale (Seca 
Model 770) with the participant wearing light clothing. Height 
and weight were screened as covariates due to the potential 
effect of body physique on muscle torque production. 
Body composition
Dual-energy x-ray absorptiometry (DXA) scans were 
completed using a Hologic Discovery-A scanner (Apex 
Softward v.5.6, Hologic Inc., Bedford, MA). Our measurements 
of lean and fat mass are precise with percent coefficients of 
variation of 0.4% and 1.3%, respectively. Lean and fat mass 
may be correlated with measures obtained from Biodex 
testing and therefore were considered as potential covariates. 
Grip strength
Grip strength of the dominant side was measured using the 
digital Grip-D grip strength dynamometer (Takei Scientific 
Instruments, Niigata-City, Japan). We adjusted the apparatus 
to the proper hand size for each participant. The participant 
then held the dynamometer with their arm relaxed and 
extended downward and squeezed the instrument as hard as 
possible for three seconds. This test was repeated two more 
times and the highest reading of the three trials was recorded. 
Data from a previously performed reliability study in our lab 
indicates that no significant learning effect is present when 
three testing sessions are performed over the course of 30 
days. The coefficient of variation for grip strength among the 
three visits was 4.4%. 
Isokinetic testing
Isokinetic testing was performed using a Biodex System 
4 (Biodex Medical Systems, Shirley, NY). Participants were 
seated with their shoulders and waist strapped to the chair 
(Figure 1). Following the manufacturer’s recommendation, 
the dynamometer was oriented at 90o with a 0o tilt. The 
seat was set at 85o tilt with the axis of rotation at the knee 
set to pass through the lateral femoral condyle in a sagittal 
plane. The participant’s distal lower leg was secured using 
Velcro strap positioned immediately proximal to the medial 
Figure 1. Positioning of the participant for isokinetic testing on the Biodex System 4 ergometer. 
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malleolus. Prior to beginning the testing, the participant was 
instructed to grab each of the side handles for support. Once 
the participant was properly positioned, they went through a 
series of 5 to 7 familiarization repetitions to get accustomed 
to the machine. The first 3 to 5 repetitions were done at very 
low effort with the final 2 repetitions being performed at 
100% effort. Familiarization repetitions were performed at 
every testing session to ensure that participants were tested 
similarly across all visits. The performance trial consisted of 
5 isokinetic knee extension and knee flexion repetitions at 
60o/second, 5 repetitions at 180o/second, and 5 repetitions 
at 300o/second. Each series of repetitions were separated 
by a one-minute rest period. Standardized feedback was 
given to every participant reminding them to complete 
the testing with maximal efforts. This feedback was given 
during the flexion phase of repetition two. The Biodex has 
been reported to be a reliable tool for measuring isokinetic 
torque production up to 300o/second (ICC=0.99, CV<2%)32. 
In addition to peak torque measurements, isokinetic testing 
was used to determine the knee flexor-to-knee extensor 
ratio. Data from a previously performed reliability study in 
our lab indicate that no effect of study visit order when three 
testing sessions were performed over the course of 30 days. 
The coefficients of variation among the three study visits 
at 60o, 180o, and 300o/sec were 6.8%, 5.8% and 6.2%, 
respectively (Supplemental Table 1).
Fatigue protocol
A fatigue protocol was utilized to examine whether or not 
individuals fatigued at a different rate at different phases of the 
menstrual cycle. The fatigue test was performed a minimum 
of 30 minutes after the initial isokinetic testing and consisted 
of participants performing a number of repeated maximal leg 
extension and flexion movements at 180o per second using 
the Biodex. The participant was considered “fatigued” when 
they performed three consecutive repetitions in which their 
peak torque in both extension and flexion were less than 
50% of the peak torque measured during the non-fatigued 
isokinetic testing. 
Knee joint laxity
Knee joint laxity was measured using the KT 1000 knee 
arthrometer with the participant lying in a comfortable 
supine position. An adjustable thigh support platform was 
placed under both legs just proximal to the popliteal space. 
A foot support platform was placed under both feet with the 
patient’s feet located in a position that allows the knee to 
be in a neutral position. All of these tests were done prior 
to (rested) and immediately following the Biodex testing 
(fatigued) to assess the effect of thigh fatigue on knee joint 
laxity. The same certified athletic trainer performed all knee 
joint laxity measurements. A reliability study was performed 
prior to the start of the study and a percent coefficient of 
variation of 4.3% was calculated for this examiner. 
Blood collection procedure
Blood was collected by a trained phlebotomist prior to any 
physical measurements taking place. The participant was 
placed in a seated position with their feet flat on the floor and 
their arm lying on the collection table. The phlebotomist used 
a BD Vacutainer blood collection kit (Becton, Dickinson and 
Company, Franklin Lakes, NJ) to collect the sample from a 
vein in the antecubital region. A total of 17 ml of blood was 
collected into a 10ml serum separation tube and a 7 ml tube 
with K3 EDTA additive. 
Estradiol-17
Plasma concentrations of estradiol (E2) were determined 
in duplicate by radioimmunoassay (RIA). Estradiol-17 
(E8875; Sigma Life Science, St. Louis, MO) was the standard 
and radioiodinated E2 (#07138228; MP Biomedicals, Solon, 
OH) was the tracer. Antisera (GDN#244 anti-estradiol-17 
6-BSA; Fort Collins, CO) was used at a dilution of 1:425,000. 
Sera (250-L) was extracted with a 4-mL volume of methyl 
tert-butyl ether. Recovery of [125I]estradiol-17 added to 
plasma before extraction averaged 96±2%. Inhibition curves 
of increasing amounts of sample were parallel to standard 
curves. Intra- and inter-assay coefficients of variation were 
Table 1. Data collected at each visit.
Procedure Early Follicular Ovulation Mid Luteal
Informed Consent X






Venipuncture X X X
Isokinetic Testing X X X
Laxity Testing X X X
Fatigue Protocol X X X
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12.8% and 12.6%, respectively. Sensitivity of the assay was 
0.4 pg/tube. 
Progesterone
Plasma concentrations of progesterone were determined 
in duplicate by RIA. Progesterone (P0130; Sigma Life 
Science; St. Louis, MO) was the standard and radioiodinated 
progesterone (#07-170126; MP Biomedicals, Solon, OH) was 
used as the tracer. Antisera (#111.2C7.3; Enzo Life Sciences, 
Farmingdale, NY) was used at a dilution of 1:700,000. 
Inhibition curves of increasing amounts of sample were 
parallel to standard curves. Intra-assay coefficient of variation 
was 8.0%. Sensitivity of the assay was 0.10 ng/tube.
Relaxin
Plasma concentrations of relaxin were determined in 
duplicate by RIA using the Relaxin 2 kit (RK-035-62, 
Phoenix Pharmaceutical, Inc, Burlington, CA) according to 
the manufacturer’s directions. Inhibition curves of increasing 
amounts of sample were parallel to standard curves. Intra-
assay coefficient of variation was 5.9%. Sensitivity of the 
assay was 7.8 pg/tube. 
Statistical analysis
Student’s t-tests were used to compare the baseline 
characteristics of the OC and non-OC groups. Linear 
mixed effects models were used to determine the effect 
of menstrual cycle phase on dependent variables while 
adjusting for covariates. Dependent variables included grip 
strength, isokinetic peak torque, repetitions to fatigue, and 
knee joint laxity. Independent variables that were tested 
included the log of estrogen and relaxin concentrations, 
menstrual cycle phase, and OC use. Covariates that were 
screened included menstrual symptoms, lean mass, fat 
mass, age, height, physical activity days, caloric intake, 
Table 2. Participant characteristics.
Non-OC (n=22)a OC (n=24)b P-Value
Height (cm) 167.0 ± 6.5 169.9 ± 7.0 NS
Lean Mass (kg) 45.3 ± 4.8 45.1 ± 5.9 NS
Fat Mass (kg) 18.5 ± 5.6 20.6 ± 6.8 NS
Age (years) 20 ± 1 20 ± 1 NS
Phys. Act. (day/wk) 5.0 ± 1.5 4.6 ± 1.5 NS
Data are presented as mean ± SD. a3 participants did not ovulate and were excluded from all analyses. b1 participant did not have complete 
data and was excluded from all analyses.
Figure 2. Marginal mean peak torque at 60o, 180o, and 300o per second (marginal mean ± SE). Data are marginal means after adjusting 
for contraception group (not significant), lean mass, and fat mass. Data were compared within different test speeds using pairwise 
comparisons using a Bonferroni adjustment.
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macronutrient intake, and caffeine intake. To determine 
whether or not changes throughout the menstrual cycle were 
different between the OC and non-OC groups, a group-by-
phase interaction was used. Final models included OC use, 
menstrual cycle phase, lean mass, and fat mass. Marginal 
means were calculated and post-hoc comparisons were 
performed using a Bonferroni adjustment with a=0.05. All 
analyses were performed using STATA 15 (StataCorp. 2017. 




Participant characteristics by OC group are given in 
Table 2. Age, height, lean mass, fat mass, and physical 
activity days per week at each visit did not differ between 
groups. No differences between groups were observed 
in the proportion of participants experiencing menstrual 
symptoms at any of the visits; however, a greater proportion 
of participants experienced menstrual symptoms during 
the early-follicular phase than the ovulatory or luteal 
phases in 7 out of 18 categories (Table 3). Total caloric 
intake, protein intake, carbohydrate intake, and caffeine 
intake 24 hours prior to each visit were not different 
among visits (Table 4).
Grip strength
Grip strength was greater at the ovulation (31.5±4.1 
kg) and mid-luteal visits (32.5±4.9 kg) than at the 
early-follicular visit (30.0±4.4 kg). No group-by-phase 
interaction was observed, indicating similar menstrual 
phase differences for non-OC and OC users. Grip strength 
was not different between the OC and non-OC group at any 
visit (Supplemental Table 2).
Isokinetic testing, fatigue, and knee joint laxity 
Extension peak torque at 60o/sec was 4% lower during 
the early-follicular visit (82.4±2.1 nM) than the ovulation 
visit (85.7±2.1 nM; p<0.05), but was not different at the mid-
luteal phase visit (84.7±2.1 nM) (Figure 2). Extension peak 
torque at 180o was 8-11% lower at the early-follicular phase 
(53.7±1.5 nM) than the ovulatory and mid-luteal phases 
(58.1±1.5 nM and 60.4±1.5 nM, respectively; both, p<0.05). 
Similarly, extension peak torque at 300o/sec was 7-8% 
lower at the early-follicular phase (42.9±1.3 nM) than the 
ovulatory and mid-luteal phases (46.3±1.3 nM and 46.6±1.3 
nM, respectively; both p<0.05). 
Flexion peak torque at 60o/sec was 8% lower at the 
early-follicular visit than the ovulation visit (39.5±1.5 
nM and 43.0±1.4 nM, respectively; p<0.05). Flexion peak 
torque at 180o/sec also was 13-14% lower at the early-
Table 3. Menstrual symptoms by phase and group.
Follicular Ovulation Luteal
NOC OC NOC OC NOC OC
I feel more irritable than normal* 33% 21% 5% 0% 10% 4%
I am experiencing menstrual cramps* 38% 54% 0% 8% 0% 4%
I am feeling more depressed than normal 10% 4% 0% 0% 0% 0%
I am experiencing more stomach pain than normal* 33% 21% 5% 0% 10% 13%
I get tired more easily* 57% 33% 10% 4% 10% 21%
I am taking a prescription for menstrual pain 0% 4% 0% 4% 0% 4%
I am feeling weak or dizzy 0% 8% 0% 0% 10% 0%
I am feeling tense or nervous 5% 13% 5% 8% 19% 8%
I am experiencing diarrhea 14% 0% 0% 0% 5% 0%
I am experiencing backaches or lower back pain* 33% 33% 19% 8% 19% 8%
I am taking OTC medication for pain* 10% 13% 0% 0% 0% 0%
I am experiencing pain in my breasts 5% 13% 0% 0% 10% 0%
I am using heat to treat my abdominal or back pain 0% 8% 0% 4% 0% 0%
I am experiencing constipation 0% 0% 5% 0% 5% 4%
I am experiencing muscle spasms in my legs 0% 0% 0% 0% 0% 0%
I am feeling more bloated than normal* 53% 38% 5% 0% 19% 17%
I am feeling more nauseous than normal 14% 4% 0% 0% 5% 8%
I am having more headaches than normal 19% 8% 0% 4% 10% 8%
Data shown are the percentage of participants who responded “Yes” to each statement. NOC = No oral contraception. OC = Oral contraception. 
Chi2 analysis revealed no between-group differences for any of the variables at any phase. *Indicates differences in the proportion of 
menstrual symptoms experienced among phases (chi2, p<0.05).
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follicular visit (28.5±1.0 nM) compared to the ovulation 
and luteal phase visits (32.6±1.0 nM and 33.0±1.0 nM, 
respectively; both, p<0.05). Results were similar for 
flexion peak torque at 300o/sec with 9-10% lower peak 
torque being observed at the early-follicular phase visit 
(28.4±1.2 nM) compared with the ovulation and luteal 
phase visits (31.7±1.2 nM and 31.1±1.2 nM, respectively; 
both p<0.05). 
The group-by-phase interaction was not significant for 
any of the extension or flexion peak torque measures, and 
extension and flexion peak torque values were not different 
between the OC and non-OC group at any visit (Supplemental 
Table 2).
Knee flexor-to-knee extensor ratio at 60o, 180o and 
300oo/second; repetitions to fatigue at 180o/second; 
and both rested and fatigued joint laxity did not change 
throughout the menstrual cycle (Table 4). 
Hormone concentrations
Hormone concentrations for the non-OC and OC groups 
at each visit are given in Table 5. During the early-follicular 
phase, participants in the non-OC group had higher 
estradiol concentrations than the OC group, (p<0.001) 
and progesterone concentrations did not differ. At both 
the ovulatory and mid-luteal phase visits, estradiol and 
progesterone concentrations were both higher in the non-
OC group than the OC group (p<0.001 for all comparisons). 
Relaxin concentrations did not differ between non-OC 
and OC groups at any visit. Significant group-by-phase 
interactions were observed for estradiol and progesterone 
Table 4. Dietary intakes, flexor to extensor ratio and knee joint laxity by cycle phase.
Early-Follicular Ovulatory Mid-Luteal
Caloric Intake (Kcal) 2180 ± 1247 1942 ± 751 1827 ± 574
Protein (g) 82 ± 41 69 ± 31 76 ± 27
Carbohydrate (g) 283 ± 171 256 ±89 226 ± 76
Fat (g) 85 ± 60 60 ± 25 73 ± 27
Caffeine (g) 44 ± 86 50 ± 88 54 ± 91
FE Ratio 60o/s (%) 49.1 ± 11.3 50.4 ± 10.4 49.3 ± 8.3
FE Ratio 180o/s (%) 54.0 ± 11.3 56.7 ± 10.2 54.4 ± 9.8
FE Ratio 300o/s (%) 67.5 ± 14.0 68.3 ± 14.7 66.6 ± 12.5
Repetitions to Fatigue 40.6 ± 8.4 40.0 ± 8.7 39.3 ± 8.6
Rested Joint Laxity (mm) 6.7 ± 2.7 6.4 ± 2.3 6.1 ± 2.1
Fatigued Joint Laxity (mm) 6.9 ± 2.2 6.4 ± 2.3 6.4 ± 1.9
Data given as means ± SD. No significant differences among visits were observed. FE Ratio = Knee flexor-to-knee extensor ratio.
Table 5. Hormone concentrations by menstrual cycle phase.
Non-OC (n=22)a OC (n=24)b P-Value
Early-Follicular Phase 
   Estradiol (pg/ml) 67 (22-110) 40 (18-81) 0.001
   Progesterone (ng/ml) 0.05 (0.04-0.13) 0.04 (0.03-0.23) NS
   Relaxin (pg/ml) 24 (8-74) 22 (10-67) NS
Ovulatory Phase
   Estradiol (pg/ml) 121 (60-330) 33 (13-109) <0.001
   Progesterone (ng/ml) 0.32 (0.03-12.26) 0.04 (0.01-0.32) <0.001
   Relaxin (pg/ml) 22 (20-47) 22 (7-67) NS
Mid-Luteal Phase
   Estradiol (pg/ml) 148 (60-298) 29 (15-67) <0.001
   Progesterone (ng/ml) 1.04 (0.03-12.21) 0.04 (0.03-0.42) <0.001
   Relaxin (pg/ml) 27 (11-90) 24 (8-60) NS
a 3 participants did not ovulate and were excluded from all analyses. b 1 participant did not have complete data from all analyses. All data 
were log-normal distributed, therefore data are presented as geometric means (95% CI).
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with concentrations of both hormones becoming elevated in 
the non-OC group after the early-follicular phase.
Discussion
The purpose of this study was to investigate changes in 
muscular strength and stamina, measured by isokinetic 
testing of the knee flexors and knee extensors, throughout 
the menstrual cycle and to determine whether or not changes 
were different between OC and non-OC users. The key 
finding from the current study is that flexion and extension 
isokinetic peak torques were lower in the early-follicular 
phase than the ovulatory and mid-luteal phases during the 
180o and 300o/sec testing. Additionally, during the 60o/sec 
testing, peak torque was greater during the ovulatory phase 
than the early-follicular phase. Particularly troubling in the 
area of ACL injury prevention is the finding of 4-11% lower 
flexion peak torque during the early-follicular phase of the 
cycle. Given the role of the hamstrings in protecting against 
anterior tibial translation, a decrease in hamstring strength 
could place women in the early-follicular phase of their cycle 
at a greater risk of suffering an ACL injury. The relationship 
between ACL injury and hamstring strength has been shown 
previously in a matched case-control study that found lower 
hamstring strength in females who went on to tear their 
ACL33. In addition to decreased lower extremity strength 
during the early-follicular phase, grip strength also was lower 
during the early-follicular phase than the ovulatory and mid-
luteal phases. This is important because it indicates a whole 
body effect rather than an isolated effect or learning effect. 
The absence of a learning effect also is supported by previous 
work that indicated a high level of test-retest reliability34 and 
mechanical reliability32 with isokinetic measurements using 
the Biodex System 4 and our results finding no change in 
three measurements taken longitudinally over a 30-day 
period (see Supplemental Table 1). 
The findings from the present study are similar to findings 
from a previous study that reported lower peak torque 
production during leg extension and flexion during the 
early-follicular phase compared to the ovulatory phase in 
female soccer players35. In the study by Dos Santos et al., 
no differences were observed in males tested at the same 
time intervals, and the authors suggested that the lower 
peak torque during the early-follicular phase may be due to 
hormonal effects that are specific to females. On the other 
hand, a study similar to ours reported no phase-specific 
differences in force, velocity, or power output during half 
squats on a Smith machine36. One explanation for why these 
findings could differ from ours could be that the nature of 
isokinetic exercise requires greater muscle recruitment 
than an isotonic movements such as a squat and therefore 
may be more sensitive to small physiological changes in 
neuromuscular performance. 
Previous studies investigating injury risk throughout 
the menstrual cycle have reported that risk of ACL injuries 
are greater early in the menstrual cycle37 and in particular 
prior to ovulation38,39. Decreased muscle strength could 
potentially increase the risk of suffering an ACL injury and 
our findings of lower peak torque in the early-follicular phase 
may indicate a potential risk factor for ACL injuries. However, 
it is important to note that other studies have reported ACL 
injury risk to be greatest during the ovulatory phase which 
is when the greatest torque production was observed in the 
current study9,40.
Significant group-by-phase interactions were observed 
for estradiol and progesterone with concentrations of both 
hormones being elevated in the non-OC group after the 
early-follicular phase. However, these hormonal fluctuations 
did not appear to affect any of the outcome measures in this 
study because no significant group-by-phase interactions 
were observed. This finding is in agreement with a previous 
study indicating no influence of reproductive hormones on 
skeletal muscle contractility41. The finding of no difference 
between the OC and non-OC groups in the study by de Jonge 
et al. and the present study are somewhat surprising given 
previously published work that reported a protective effect 
of oral contraception on ACL injury risk24,25. However, it is 
important to consider that hormonal fluctuations are not the 
only physiological change throughout the menstual cycle. 
In the absence of a hormone-related effect, one potential 
explaination for lower skeletal muscle strength during the 
follicular cycle is low iron concentrations. While this was not 
measured in the present study, the negative effect of low 
iron concentrations and the benefits of iron supplementation 
in female athetes has been well documented in both 
submaximal and maximal exercise42. It has previously been 
reported that as many as 30% of all female collegiate 
athletes are iron deficient43 and therefore any small decrease 
in iron concentration due to menstrual bleeding could have 
significant implications on neuromuscular performance. 
Furthermore, one study indicated that iron concentrations 
were lower during the early follicular phase than the ovulatory 
phase44. If iron concentrations are lower during the early 
follicular phase than the ovulatory or luteal phases, then 
theoretically a decrease in maximal exercise performance 
may be expected. Future studies should be performed to 
determine if menstrual phase changes in musculoskeletal 
performance can be attenuated by using supplemental iron. 
Limitations
A limitation of this study is the reliance on each participant 
completing maximal contractions during muscle testing. 
We addressed this limitation by using the peak torque 
measurement from a total of five repetitions rather than the 
average peak torque. We also compared the coefficient of 
variation among repetitions to determine if any participants 
had a within-test variability that was outside the norm for 
the entire sample. An additional limitation is that the study 
only utilized a single menstrual cycle and each participant 
began the study during the early-follicular phase. While this 
may introduce the chance of a learning effect, this is not 
likely based on findings from a reliability trial that showed no 
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increases in isokinetic peak torque or grip strength among 
three visits performed over 30 days (see Supplemental Table 
1). Additionally, the percent difference among measurements 
in the present study was greater than the coefficient of 
variation previously observed in the reliability study for all 
measurements except the 60o/second isokinetic peak torque 
where the percent difference between the early-follicular and 
ovulation phases was smaller than the percent CV. 
Conclusion
In conclusion, grip strength and peak torque were lower 
during the early-follicular phase than the ovulatory and 
mid-luteal phases. A surpising finding was that changes in 
peak torque and grip strength throughout the cycle were 
similar regardless of whether or not the female was taking 
oral contraceptives. Given the role of oral contraceptives in 
stabilizing hormone concentrations throughout the cycle, 
the results of this study indicate that cycle phase dependent 
differences in strength may not be explained by sex hormone 
fluctuations. Future studies investigating the role of other 
hormones or non-hormonal factors as it relates to ACL 
risk factors throughout the menstrual cycle are necessary 
to determine appropriate strategies for attenuating the 
strength deficits observed in the present study.
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Supplemental Table 1. Reliability of grip strength and isokinetic peak torque.
Baseline Mean1 CV2 r3 p-value4
Grip Strength 44.7 ± 15.9 kg 4.4 0.04 0.96
Ext. Peak Torque 60o/sec 150.1 ± 55.2 Nm 6.8 0.08 0.89
Ext. Peak Torque 180o/sec 103.3 ± 31.2 Nm 5.8 0.09 0.83
Ext. Peak Torque 300o/sec 80.8 ± 22.2 Nm 6.2 0.12 0.78
Joint Laxity 5.8 ± 1.8 mm 4.3 0.01 0.99
1Data are means ± SD at the baseline visit. 2Percent coefficient of variation. 3Correlation-coefficient for the relationship between outcome 
measures and visit. 4P-value for the correlation between outcome measures and visit number.
Supplemental Table 2. 
Early-Follicular Ovulatory Mid-Luteal
Non-OC OC Non-OC OC Non-OC OC
Grip Strength (kg) 30.2 ± 4.2 29.9 ± 4.7 31.9 ± 3.7 31.1 ± 4.5 32.9 ± 5.0 32.9 ± 5.0
Extension Peak Torque
   60o/sec (Nm) 80.6 ± 16.1 84.1 ± 13.2 84.7 ± 15.8 86.7 ± 13.9 83.9 ± 16.5 85.4 ± 12.2
   180o/sec (Nm) 51.8 ± 9.9 55.4 ± 9.4 55.6 ± 10.7 60.4 ± 10.2 58.9 ± 11.5 61.8 ± 9.8
   300o/sec (Nm) 41.2 ± 9.5 44.5 ± 7.6 44.1 ± 9.1 48.3 ± 8.9 45.5 ± 9.3 47.6 ± 8.1
Flexion Peak Torque
   60o/sec (Nm) 37.5 ± 6.7 42.0 ± 11.2 43.9 ± 15.9 42.0 ± 7.5 40.6 ± 9.3 42.2 ± 8.5
   180o/sec (Nm) 26.8 ± 7.9 30.7 ± 6.8 30.3 ± 7.7 34.9 ± 6.8 30.7 ± 6.9 34.2 ± 6.9
   300o/sec (Nm) 27.4 ± 7.7 30.2 ± 8.0 28.0 ± 7.4 34.9 ± 9.7 29.0 ± 7.6 33.1 ± 7.0
